Clinical Trial Update: Effects of Triiodothyronine (T3) in Ischemic Heart Failure [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluating Triiodothyronine (T3) for ischemic heart failure is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure

Drugs mentioned

• Triiodothyronine (T3) (triiodothyronine)

Snippet

Sponsor: Emory University | Conditions: Heart Failure | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING